Pharming Group N.V.: Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of

Related Keywords

United States ,Netherlands ,United Kingdom ,London ,City Of ,Amsterdam ,Noord Holland ,America ,Ethan Metelenis ,Heather Robertson ,Dan Caley ,Anurag Relan ,Linkedin ,Nasdaq ,Exchange Commission ,Pharming Groupnv Euronext Amsterdam ,Prnewswire Pharming Groupnv ,European Medicines Agency ,Pharming Group ,Committee For Medicinal Products Human Use ,Lifespring Life Sciences Communication ,Investor Relations Corporate Communications ,Marketing Authorisation Application ,Medicinal Products ,Human Use ,Chief Medical Officer ,Activated Phosphoinositide ,Euronext Amsterdam ,North America ,Middle East ,Annual Report ,Allergy Clin ,Rev Allergy ,Investor Relations ,Corporate Communications ,Spring Life Sciences Communication ,Pharming ,Group ,Ubmits ,Marketing ,Authorisation ,Application ,European ,Medicines ,Agency ,Eniolisib ,